YUFLYMA® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar ...

CIDP is closely related to Guillain-Barre syndrome (GBS), but they're not ... and involve damage to your myelin. But MS affects your central nervous system, including your brain and spinal cord ...

HADLIMA™ (adalimumab-bwwd) injection, 40 mg/0.4 mL & 40 mg/0.8 mL is now interchangeable with all high- and low-concentration presentations ...

HADLIMA™ (adalimumab-bwwd) injection, 40 mg/0.4 mL & 40 mg/0.8 mL is now interchangeable with all high- and low-concentration presentations (autoinjector, prefilled syringe, and single-dose vial) of ...

He was diagnosed with Guillain-Barré syndrome secondary to COVID-19 and started on intravenous ... Stimulation was performed with a bipolar stimulator employing 0.1 ms duration squared pulses and ...

Guillain-Barré Syndrome is a rare condition that attacks a person's nerves. It can lead to muscle weakness and sometimes paralysis. When Rob was finally able to go home, his family turned part of ...

The singer-songwriter, 49, opened up about his health following his 2023 diagnosis with Guillain-Barré syndrome in an interview with Vulture published on Wednesday, May 14. "I’m okay.

The Task Force of the European Academy of Neurology and the Peripheral Nerve Society published updated guidelines in 2024 on the diagnosis and treatment of Guillain-Barré syndrome (GBS), which ...

Guillain-Barré syndrome (GBS) is an acute inflammatory neuropathy that can lead to severe weakness of the limbs, face, and respiratory muscles. Its pathophysiology involves autoantibodies that ...

BRISBANE, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with ...